Animace načítání

Stránka se připravuje...

Přihlásit se Registrovat se
28 428 právních předpisů

Další údaje zde

Technická podpora

Poskytujeme technickou podporu zdarma

Zavolejte nám

+420 777 717 492

Plné znění - 32020R1182

  1. Úvodní strana
  2. Právní předpisy EU
  3. Plné znění - 32020R1182

Na co čekáte? Nečekejte už ani minutu.
Získejte přístup na tento text ještě dnes. Kontaktujte nás a my Vám obratem uděláme nabídku pro Vás přímo na míru.

Chci získat výhodný přístup

NAŘÍZENÍ KOMISE V XXXXXXXXX XXXXXXXXX (XX) 2020/1182

xx dne 19. xxxxxx 2020,

kterým xx xxx účely přizpůsobení xxxxxxxxxxx x vědeckému xxxxxxx mění xxxx 3 xxxxxxx XX xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (XX) x. 1272/2008 o xxxxxxxxxxx, označování x xxxxxx xxxxx x xxxxx

(Xxxx s xxxxxxxx xxx EHP)

EVROPSKÁ XXXXXX,

x xxxxxxx na Xxxxxxx x fungování Xxxxxxxx xxxx,

x ohledem xx xxxxxxxx Xxxxxxxxxx parlamentu x Rady (XX) x. 1272/2008 xx xxx 16. xxxxxxxx 2008 o xxxxxxxxxxx, xxxxxxxxxx x balení xxxxx a směsí, x změně x xxxxxxx xxxxxxx 67/548/XXX x 1999/45/XX x x xxxxx nařízení (XX) č. 1907/2006&xxxx;(1), x xxxxxxx xx xx. 37 xxxx. 5 uvedeného xxxxxxxx,

xxxxxxxx x xxxxx xxxxxxx:

(1)

Xxxxxxx 3 x xxxxx 3 xxxxxxx XX xxxxxxxx (XX) č. 1272/2008 xxxxxxxx xxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx a xxxxxxxx nebezpečných látek xx xxxxxxx xxxxxxxx xxxxxxxxxxx x xxxxxxx 2 xx 5 xxxxxxx I xxxxxxxxx xxxxxxxx.

(2)

Xxxxxxxx agentuře pro xxxxxxxx xxxxx („xxxxxxxx“) xxxx x souladu x xxxxxxx 37 xxxxxxxx (ES) x. 1272/2008 xxxxxxxxxx xxxxxx xx zavedení xxxxxxxxxxxxx xxxxxxxxxxx x označení xxxxxxxxx látek x xxxxxxxxxxx nebo xxxxxxx xxxxxxxxxxxxxxx klasifikací a xxxxxxxx xxxxxxxxx jiných xxxxx. Xx základě xxxxxxxxxx&xxxx;(2) x xxxxx xxxxxxx, xxxxx xxxxx Xxxxx xxx xxxxxxxxxx xxxxx („RAC“) xxxxxxxx, xxxxx x xxxxxxxxxx xxxxxxxxxxxx stran, xx xxxxxx xxxxxx, aktualizovat xx xxxxxx harmonizované xxxxxxxxxxx x xxxxxxxx xxxxxxxxx xxxxx. Xxxxxxx xxxxxxxxxx výboru RAC xxxx:

—

xxxxxxxxxx xx dne 8. xxxxxx 2018 xxxxxxx xxxxxxxx xxxxxxx... %[X ≤ 70 %],

—

xxxxxxxxxx ze dne 9. xxxxxx 2018 xxxxxxx xxxxxx x xxxxxxx xxxxxxx (o xxxxxxx &xx; 3 μx,xxxxx &xx; 5 μx x xxxxxx xxxxx ≥ 3:1),

—

xxxxxxxxxx xx dne 8. xxxxxx 2018 xxxxxxx xxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxx(xxxxx)xxxxxx,

—

xxxxxxxxxx xx xxx 8. června 2018 xxxxxxx xxxx(2-xxxxxxxxxxxxx)xxxxxxxxxxx, 6-(2-xxxxxxxxxxxxx)-6-xxxxx-2,5,7,10-xxxxxxxx-6-xxxxxxxxxxxx,

—

xxxxxxxxxx ze dne 8. června 2018 xxxxxxx xxxxxxxx-xxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx xxxxxxxxxxx xxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxx (X-xxxxxxx-X-xxxxxxxxxxxxxxxxxxxxxxxx-X,X’)-xxxx, xxx(X-xxxxxxxxxx-xxxxxxxxx-xxxxx)-xxxx, [Cu-HDO],

—

stanovisko xx xxx 14. září 2018 ohledně dioktyltin-dilaurátu, [1] xxxxxxxx, dioktyl-, xxx(xxxx xxxxxxx) derivátů [2],

—

xxxxxxxxxx xx xxx 30. listopadu 2018 xxxxxxx xxxxxxx[xxx,x]xxxxxxxx, xxxxxxx[x,x]xxxxxx,

—

xxxxxxxxxx xx dne 9. xxxxxx 2018 ohledně xxxxxxxxxx (XXX), (1XX,2XX,5XX;1XX,2XX,5XX)-2-(4-xxxxxxxxxxx)-5-xxxxxxxxx-1-(1X-1,2,4-xxxxxxx-1-xxxxxxxx)xxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx xxx(2-(2-xxxxxxxxxxxxx)xxxxx)xxxxxx, xxxxxxxxxx,

—

xxxxxxxxxx ze xxx 8. xxxxxx 2018 xxxxxxx xxxxxxxxxxxxxx (XXX), (2RS,3RS)-1-(4-chlorofenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-olu,

—

stanovisko xx xxx 8. xxxxxx 2018 xxxxxxx 2,2-xxx(xxxxxxxxxx)xxxxxx-1,3-xxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxx, (2X)-3,7-xxxxxxxxxxxx-2,6-xxxx-1-xxx,

—

xxxxxxxxxx xx xxx 28. xxxxx 2019 xxxxxxx 2-(4-terc-butylbenzyl)propionaldehydu,

—

stanovisko xx xxx 9. xxxxxx 2018 xxxxxxx XXXX-xxxxxxxxxx (XXX), X-xxxxx (4-xxxxx-2-xxxxxxxxxxxx)xxxxxxxxxxxxx, X-xxxxx 4-xxxxx-x-xxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxx-xxxxxxx,

—

xxxxxxxxxx xx dne 14. září 2018 xxxxxxx 4-{[(6-xxxxxxxxxxxxx-3-xx)xxxxxx](2,2-xxxxxxxxxxxxx)xxxxx}xxxxx-2(5X)-xxx, xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxxxx-xxxxxxx (ISO), xxxxxx 4- [(4,5-xxxxxxx-3-xxxxxxx-4-xxxxxx-5-xxx-1X-1,2,4-xxxxxxx-1-xx)xxxxxxxxxxxxxxxxx]-5-xxxxxxxxxxxxx-3-xxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 9. xxxxxx 2018 ohledně X-(+)-xxxxxx xxxxxxxx, (2S)-2-hydroxypropanové kyseliny,

—

stanovisko xx xxx 9. xxxxxx 2018 ohledně 2-xxxxxxxxxxxx-xxxxxxxx,

—

xxxxxxxxxx ze xxx 8. června 2018 xxxxxxx glyoxylové xxxxxxxx …%,

—

xxxxxxxxxx xx dne 14. xxxx 2018 xxxxxxx natrium-N-(hydroxymethyl)glycinátu, [xxxxxxxxxxx xxxxxxxx x natria-N-(hydroxymethyl)glycinátu],

—

stanovisko xx xxx 30. xxxxxxxxx 2018 xxxxxxx (xxxxx-XXX-xxxxx)xxxxxxxxxxx xxxxxxxxxx, xxxxxxxxxx(xxxxxxx)xxxxxx-1-xxxxx, xxxxxxxx xxxx, [X-XXX],

—

xxxxxxxxxx xx dne 14. xxxx 2018 xxxxxxx xxxxxxxxxxx-xxxxxxxxxxx, X-xxxxx-X,X-xxxxxxxxxxxxxxxxx-1-xxxxxxx-xxxxx-xxxxxxx, xxxxxxxxxxx-xxxxx-xxxxxxx [XXX],

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx (2XX)-2-[4-(4-xxxxxxxxxxx)-2(xxxxxxxxxxxxxxx)xxxxx]-1-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-2-xxx, xxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 30. xxxxxxxxx 2018 ohledně xxxxxxxxxxxxxxxx (XXX), 1-(4-{4-[5-(2,6-xxxxxxxxxxxx)-4,5-xxxxxxx-1,2-xxxxxx-3-xx]-1,3-xxxxxxx-2-xx}xxxxxxxxx-1-xx)-2-[5-xxxxxx-3-(xxxxxxxxxxxxxxx)-1X-xxxxxxx-1-xx]xxxxxxxx,

—

xxxxxxxxxx xx dne 14. xxxx 2018 xxxxxxx xxxxxxxxx-xxxxx, (T-4)-bis[1-(hydroxy-kappa-O)pyridin-2(1H)-thionát-kappa-S]zinku,

—

stanovisko ze xxx 30. xxxxxxxxx 2018 ohledně 3-xxxxx-4-(xxxxxxxxxxx)-1-[3-xxxxxxxxxxxxxx)xxxxx]xxxxxxxxxx-2-xxx, xxxxxxxxxxxxxxx (ISO),

—

stanovisko xx xxx 30. xxxxxxxxx 2018 xxxxxxx 4,5-xxxxxxx-2-xxxxx-2X-xxxxxxxxxx-3-xxx, [XXXXX],

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx 2-methyl-1,2-benzothiazol-3(2H)-onu, [XXXX],

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx 3-(xxxxxxxxxxxxx)-1-xxxxxx-X-(3‘,4’,5’xxxxxxxxxxxxxxx-2-xx)xxxxxxx-4-xxxxxxxxxxx, xxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. června 2018 xxxxxxx X-(xxxxxxxxxxxxx)xxxxxxxxxx, xxxxxxxxxxxxxxxxxx, [NMA],

—

stanovisko xx xxx 15. října 2018 ohledně 5-xxxxx-1,3-xxxxxxxx-X-[2-(4-xxxxxxxxxxxx-2-xx)xxxxx]-1X-xxxxxxx-4-xxxxxxxxxxx, 2’-[(XX)-1,3-xxxxxxxxxxxxx]-5-xxxxx-1,3-xxxxxxxxxxxxxxx-4-xxxxxxxxxxxxx, xxxxxxxxxx,

—

xxxxxxxxxx ze xxx 30. xxxxxxxxx 2018 ohledně xxxxxxxxxxxxx (XXX), xxxxxxxxx [(2S)-3-methyl-1-{[1-(4-methylfenyl)ethyl]amino}-1-oxobutan-2-yl]karbamátu,

—

stanovisko xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxx (ISO), X-xxxxx-4,5-xxxxxxxx-2(xxxxxxxxxxxxxx)xxxxxxx-3-xxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxx, výtažku [xxxx xxxxxxxx xx xxxxxxx xx xxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx bez xxxxxxxx, xxxxxxxxxxx xxxxxxxxxxxxxx xxxxxx xxxxxxxxx],

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx xxxxxxxx xxxxxxx …%[C> 70 %],

—

xxxxxxxxxx x 9. xxxxxx 2018 ohledně xxxxxxxxxxxxxxxxxxxxxxxxxxxx, [X4],

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx pirimifos-methylu (XXX), O-[2-(diethylamin)-6-methylpyrimidin-4-yl]-O,O-dimethyl-fosforthioátu,

—

stanovisko xx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxx,

—

xxxxxxxxxx ze xxx 14. xxxx 2018 xxxxxxx xxxxxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx 2-xxxxxxxxxx-10-xxxxx-4,4-xxxxxxx-7-xxx-8-xxx-3,5-xxxxxx-4-xxxxxxxxxxx-xxxxxxxxx, [XXXX],

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxx,

—

xxxxxxxxxx xx dne 14. xxxx 2018 ohledně 2-xxxxxxxxxxxxxx, xxxxxxxxxxxxx-xxxxxxxxx-xxxxxx,

—

xxxxxxxxxx ze xxx 30. xxxxxxxxx 2018 ohledně x-xxx(2,3-xxxxxxxxxxxx)xxxxxxx, xxxxxxxxxx-xxxxxxxxxx-xxxxxx,

—

xxxxxxxxxx ze xxx 14. xxxx 2018 xxxxxxx xxxxxxxxxx-xxxxxxx (XXX), xxxxxx 2-[N-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)-N-methylkarbamoylsulfamoyl]benzoátu,

—

stanovisko ze xxx 8. xxxxxx 2018 ohledně xxxxxxxxxxxxx (XXX), xxxxxx (X)-2-{2-[6-(2-xxxxxxxxxxx)xxxxxxxxx-4-xxxxx]xxxxx}-3-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 ohledně xxxxxxxxxxxx (ISO), (XX)-2-xxxxxx-2,3-xxxxxxx-3,3-xxxxxxxxxxxxxxxxxx-5-xx-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 ohledně 2,4-xxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx mesotrionu (XXX), 2-[4-(xxxxxxxxxxxxxx)-2-xxxxxxxxxxxx]-1,3-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 30. xxxxxxxxx 2018 xxxxxxx okthilinonu (XXX), 2-xxxxx-2X-xxxxxxxxxx-3-xxx, [XXX],

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxxx (XXX), 3-hydroxy-5-methylisoxazolu,

—

stanovisko ze xxx 30. listopadu 2018 ohledně xxxxxxxxxxxx (XXX), xxxxx-5-(4-xxxxxxxxxx)-X-xxxxxxxxxx-4-xxxxxx-2-xxx-3-xxxxxxxxxxx-xxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 9. března 2018 xxxxxxx xxxxxxxxxxx (XXX), (X)-4,5-xxxxxxx-6-xxxxxx-4-(3-xxxxxxxxxxxxxxx-xxxxx)-1,2,4-xxxxxxx-3(2X)-xxx,

—

xxxxxxxxxx ze xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxx (XXX), reakční xxxxx: [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxx-xxxxxxxxxxxxxx, [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxxxx-xxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 butanon-oximu, xxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 8. xxxxxx 2018 xxxxxxx bis(α,α-dimethylbenzyl)-peroxidu,

—

stanovisko xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxx 2-(1-(xxxxxxxxxxxxxxxxxxxxxxxx) xxxxxxxxx)xxxxxxxx, xxxxx 2-[4-(xxxxxxxxxxx)-2-xxxxxxxxxxxxxx]xxxxxxxx.

(3)

Xxxxx xxx x xxxxx xxxxx (číslo XXX 7439–92–1 a xxxxxxxx xxxxx 082–013–00–1 (xxxxx x xxxxxx; [xxxxxx xxxxxx &xx; 1 xx];) x 082–014–00–7 (xxxxxxxx olovo; [průměr xxxxxx ≥ 1 xx];)), RAC xx xxxx stanovisku xx xxx 30. xxxxxxxxx 2018 navrhl použít xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx xx celistvou x xxxxxxxxx xxxxx. Xxxxx xxxxxxxx x nižší xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxx, xxxxxx struktuře xxxxx, xx specifické xxxxxxx výrobě prášku x xxxxxxxx k xxxxx environmentální klasifikaci x xxxxxxxxxx a xxxxxxxxxx xxxxx jiných xxxx x xxxxxxxxxxxx xxxxxxxxx x xxxxxxx XX xxxx XXX xxxxxxx další xxxxxxxxx xxxx, xxx má xxx xx xxxxxxxxx x xxxxxxxxx xxxxx xxxxx xxxxxxx stejná xxxxxxxxxxxxxxx xxxxxxxxxxx. Kromě xxxx xxxx xxxxxxxxxx xxxx vědecké xxxxxxxx, x nichž vyplývá, xx environmentální xxxxxxxxxxx xxx xxxxxxxxx formu, xxx xx xxxxxxxxxx xxxxxxxxxx xxxxxx XXX, xxxxxx xxx xxxxxx. Xxxxxxxxxxxxxxx xxxxxxxxxxx pro xxxxxxxxx formu xxxxx xxxxxx zařazena xx xxxxxxx XX xxxxxxxx (XX) x. 1272/2008, xxxxx XXX nebude xxx možnost xxxxxxxxx xxxxxxxxxx xxxxxxxxxx.

(4)

Xxxxx xxx x xxxxx 2-butoxyethanol, xxxxxxxxxxxxx-xxxxxxxxx-xxxxx, (číslo CAS 111-76-2), xxx třídu xxxxxxxxxxxxx „xxxxxx toxicita (xxxxxxxxx)“ xxxx xxxxxxxxxx xxxx xxxxxxx poznatky, xx xxxxxxx vyplývá, xx klasifikace xxx xxxx třídu xxxxxxxxxxxxx xxxxxxxxxxxx ve xxxxxxxxxx xxxxxx RAC, xxx xx xxxxxxx xx xxxxxxxx xxxxxxx, xxxxxx xxx xxxxxx. Tato xxxxx xxxxxxxxxxxxx xx xxxxx xxxxxx xxx x xxxxxxx VI xxxxxxxx (ES) č. 1272/2008 xxxxxxx, xxxxx XXX nebude xxx xxxxxxx xxxxxxxxx x xxxxx xxxxx xxxxxxxxxx xxxxxxxxxx xxxxxxxxxx; všechny xxxxxxx třídy nebezpečnosti, x kterých xxxxxxxxx xxxxxxxxxx výboru RAC, xx xxxxxxxx xxx xxxx.

(5)

Xxxxxxxx (XX) č. 1272/2008 by xxxxx xxxx být xxxxxxxxxxxxx xxxxxxxx změněno.

(6)

Dodržování xxxxxx xxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx xx nemělo xxx, x xxxxxxxx xxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx, xxxxxxxxxx xxxxx, xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx xxxx xx to, xxx přizpůsobili xxxxxxxxxx x xxxxxx xxxxx x směsí xxxxx xxxx xxxxxxxxxxx klasifikacím x xxxxxxx xxxxxxxxx xxxxxx. Tato xxxx xx xxxxxx xxxxxxxx x tomu, xxx xxxxxxxxxx měli dostatek xxxx přijmout xxxxxxxx xxxxx k xxxxxxxxx xxxxxxxx xxxxxxxxxx dalších xxxxxxxx požadavků, xxxxx xxxxxxxx x důsledku xxxx xxxxxxxxxxx podle xxxxxx xxxxxxxx. Tyto xxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxx x xx. 22 odst. 1 xxxx. x) xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (XX) x. 1907/2006&xxxx;(3) nebo xxxxxxxxx xxxxxxxxx v xxxxxx 50 xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (XX) x. 528/2012&xxxx;(4).

(7)

Xxxxxxxxxxx by však xxxx xxx xxxxxxxx, xxx mohli nová xxxxxxxxxx xxxxxxxx xx xxxxxxxxxxx, xxxxxxxxxx x xxxxxx xxxxxxxxxx xxxxxxxxxx xxxxx dnem použitelnosti xxxxxx nařízení. Xx xx x xxxxxxx x přístupem xxxxx xx. 61 xxxx. 2 xxxxxxxx (XX) x. 1272/2008,

XXXXXXX TOTO XXXXXXXX:

Xxxxxx 1

Změny xxxxxxxx (XX) x. 1272/2008

Xxxxxxx 3 x části 3 xxxxxxx VI xxxxxxxx (XX) x. 1272/2008 xx xxxx x xxxxxxx s xxxxxxxx xxxxxx nařízení.

Xxxxxx 2

Vstup x xxxxxxxx x xxxxxxxxxxxx

Xxxx xxxxxxxx xxxxxxxx v xxxxxxxx dvacátým xxxx xx xxxxxxxxx v Xxxxxxx xxxxxxxx Xxxxxxxx xxxx.

Xxxxxxx se xxx xxx 1. xxxxxx 2022.

Xxxxxxxx od xxxxxxx xxxxxxxxxxx tohoto článku xxxxx xxx látky x xxxxx klasifikovány, xxxxxxxxxx x xxxxxx x xxxxxxx x xxxxxxxxx (XX) x. 1272/2008 ve znění xxxxxx nařízení xxxxx xxxxx dnem 1. xxxxxx 2022.

Toto xxxxxxxx xx xxxxxxx x celém xxxxxxx a xxxxx xxxxxxxxxx ve všech xxxxxxxxx xxxxxxx.

X Xxxxxxx xxx 19. května 2020.

Xx Xxxxxx

Xxxxxx XXX XXX LEYEN

předsedkyně

(1)  manaÚř. xxxx. X 353, 31.12.2008, x. 1.

(2)&xxxx;&xxxx;Xxxxxxxxxx jsou xxxxxxxx xx xxxx xxxxxxxxxxx stránce: xxxxx://xxxx.xxxxxx.xx/xxxxxxxx-xx-xxx-xxxxxxxxxx-xxxxx-xxxxxxx/-/xxxxxxx/xxxx/-/xxXxxxxx/-/xxxXxxxxx/-/xxx_xxxxxxxXxxx/-/xxx_xxxxxxxXx/-/xxx_xxxxxx_xxxxxx/Xxxxxxx+Xxxxxxx/xxx_xxxxxxxxxXxxx/-/xxx_xxxxxxxxxXx/-/xxx_xxxxxxxx_xxxxxxxxxxXxxx/-/xxx_xxxxxxxx_xxxxxxxxxxXx/-/xxx_xxxxxxxx_xxxxxxxxXxxx/-/xxx_xxxxxxxx_xxxxxxxxXx/-/xxx_xxxxxxxx_xxxxxx/-/xxx_xxxxxxxxx/-/xxx_xxxxxxxxxxXxxx/-/xxx_xxxxxxxxxxXx/-/xxx_xxxxxxxxxx_xxxxxxxxx/-/

(3)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (XX) č. 1907/2006 xx xxx 18. prosince 2006

x xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx x xxxxxxxxx xxxxxxxxxx xxxxx, x zřízení Xxxxxxxx xxxxxxxx xxx xxxxxxxx xxxxx, x xxxxx směrnice 1999/45/XX x o xxxxxxx xxxxxxxx Xxxx (EHS) x. 793/93, xxxxxxxx Xxxxxx (XX) x. 1488/94, směrnice Rady 76/769/XXX x směrnic Xxxxxx 91/155/EHS, 93/67/XXX, 93/105/XX x 2000/21/ES (Xx. xxxx. X 396, 30.12.2006, x. 1).

(4)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (XX) x. 528/2012 ze xxx 22. xxxxxx 2012

x dodávání biocidních xxxxxxxxx xx xxx x xxxxxx xxxxxxxxx

(Xx. xxxx. X 167, 27.6.2012, x. 1).

XXXXXXX

X příloze XX xxxxxxxx (XX) x. 1272/2008 se tabulka 3 v xxxxx 3 mění xxxxx:

1)

Xxxxxxxx xx tyto xxxxxxx:

Xxxxxxxx xxxxx

Xxxxxxxx xxxxx

Xxxxx XX

Xxxxx XXX

Xxxxxxxxxxx

Xxxxxxxx

Xxxxxxxxxx xxxxxxx. xxxxxx, xxxxxxxxxxxxx faktory x XXX

Xxxxxxxx

Xxxx tříd a xxxxxxxxx xxxxxxxxxxxxx

Xxxx xxxxxxxxxxxx xxx o xxxxxxxxxxxxx

Xxxx xxxxxxxxxxx symbolů a xxxxxxxxxx xxxx

Xxxx standardních xxx x xxxxxxxxxxxxx

Xxxx xxxxx. xxxxxxxxxxxx xxx x nebezpečnosti

„007-030-00-3

kyselina dusičná …% [X ≤ 70 %]

231-714-2

7697-37-2.

Ox. Liq. 3

Xxxxx Tox. 3

Xxxx Xxxx. 1 X

X272

X331

X314

XXX03

XXX06

XXX05

Xxx

X272

X331

X314

XXX071

Xx. Xxx. 3; X272: X ≥ 65 %

xxxxxxxxx: ATE = 2,65 xx/x (páry)

Skin Xxxx. 1 X; X314: X ≥ 20 %

Skin Xxxx. 1X; H314: 5 % ≤ X &xx; 20 %

X“

„014-048-00-5

xxxxxx x xxxxxxx xxxxxxx (x průměru < 3 μx, xxxxx &xx; 5 μx x s xxxxxxx xxxxx ≥ 3:1)

206-991-8

409-21-2

308076-74-6

Xxxx. 1X

X350x

XXX08

Xxx

X350x“

„014-049-00-0

xxxxxxxxxxxxxxxxxxxx; xxxxxxxxxx(xxxxx)xxxxx

220-449-8

2768-02-7

Xxxx Xxxx. 1X

X317

XXX07

Xxx

X317“

„014-050-00-6

xxxx(2-xxxxxxxxxxxxx)xxxxxxxxxx;

6-(2-xxxxxxxxxxxxx)-6-xxxxx-2,5,7,10-xxxxxxxx-6-xxxxxxxxxxx

213-934-0

1067-53-4

Xxxx. 1X

X360XX

XXX08

Xxx

X360XX“

„016-098-00-3

xxxxxxxx-xxxxxxxx

210-871-0

624-92-0

Xxxx. Liq. 2

Xxxxx Xxx. 3

Acute Xxx. 3

XXXX XX 3

XXXX XX 1

Eye Xxxxx. 2

Xxxx Xxxx. 1

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

H225

H331

H301

H336

H370 (horní xxxxxxx xxxxx, vdechnutí)

H319

H317

H400

H410

GHS02

GHS06

GHS08

GHS09

Dgr

H225

H331

H301

H336

H370 (xxxxx xxxxxxx xxxxx, xxxxxxxxx)

X319

X317

X410

xxxxxxxxx: XXX = 5 xx/x (páry)

orální: XXX = 190 xx/xx TH

M = 1

X = 10“

„029-024-00-X

granulovaná xxx;

[xxxxx xxxxxx: xx 0,9 mm a xx 6,0 mm; xxxxx xxxxxx: xx 0,494 do 0,949 xx]

231-159-6

7440-50-8

Xxxxxxx Xxxxxxx 2

X411

XXX09

X411“

„029-025-00-5

xxx(X-xxxxxxx-X-xxxxxxxxxxxxxxxxxxxxxxxx-X,X’)xxx;

xxx(X-xxxxxxxxxx-xxxxxxxxx-xxxxx)-xxx;

[Xx-XXX]

239-703-4

312600-89-8

15627-09-5

Xxxx. Xxx. 1

Xxxxx Tox. 4

XXXX RE 2

Xxx Xxx. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Chronic 1

X228

X302

X373 (xxxxx)

X318

X400

X410

XXX02

XXX07

XXX08

XXX05

XXX09

Xxx

X228

X302

X373 (xxxxx)

X318

X410

xxxxxx: ATE = 360 xx/xx XX

X = 1

X = 1“

„050-031-00-9

xxxxxxxxxx-xxxxxxxx; [1]

stannan, xxxxxxx-, xxx(xxxx xxxxxxx) xxxxxxxx [2]

222-883-3 [1] 293-901-5 [2]

3648-18-8 [1] 91648-39-4 [2]

Repr. 1B

STOT XX 1

X360X

X372 (imunitní xxxxxx)

XXX08

Xxx

X360X

X372 (imunitní systém)“

„601-092-00-0

dibenzo[def,p]chrysen;

dibenzo[a,l]pyren

205-886-4

191-30-0

Carc. 1X

Xxxx. 2

X350

X341

XXX08

Xxx

X350

X341

Xxxx. 1X; X350: C ≥ 0,001 %“

„603-237-00-3

xxxxxxxxx (XXX);

(1XX,2XX,5XX;1XX,2XX,5XX)-2-(4-xxxxxxxxxxx)-5-xxxxxxxxx-1-(1X-1,2,4-xxxxxxx-1-xxxxxxxx)xxxxxxxxxxxxx

–

125225-28-7

115850-69-6

115937-89-8

Xxxx. 1X

Xxxxx Xxx. 4

STOT XX 2

Aquatic Xxxxxxx 1

X360X

X302

X373 (xxx, kůže, xxxxx)

X410

XXX08

XXX07

XXX09

Xxx

X360X

X302

X373 (oči, xxxx, xxxxx)

X410

xxxxxx: XXX = 500 xx/xx XX

X = 100“

„603-238-00-9

xxx(2-(2-xxxxxxxxxxxxx)xxxxx)-xxxxx; xxxxxxxxx

205-594-7

143-24-8

Xxxx. 1X

X360XX

XXX08

Xxx

X360XX“

„603-239-00-4

xxxxxxxxxxxxx (ISO);

(2RS,3RS)-1-(4-chlorfenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-ol

–

76738-62-0

Repr. 2

Xxxxx Xxx. 4

Xxxxx Xxx. 4

Xxx Irrit. 2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X361x

X332

X302

X319

X400

X410

XXX08

XXX07

XXX09

Xxx

X361x

X332

X302

X319

X410

xxxxxxxxx: XXX = 3,13 xx/x (xxxxx xxxx xxxx)

xxxxxx: XXX = 490 xx/xx XX

X = 10

X = 10“

„603-240-00-X

2,2-xxx(xxxxxxxxxx)xxxxxx-1,3-xxxx

221-967-7

3296-90-0

Xxxx. 1X

Xxxx. 1X

X350

X340

XXX08

Xxx

X350

X340“

„603-241-00-5

xxxxxxxx;

(2X)-3,7-xxxxxxxxxxxx-2,6-xxxx-1-xx

203-377-1

106-24-1

Xxxx Xxxx. 1

X317

XXX07

Xxx

X317“

„605-041-00-3

2-(4-xxxx-xxxxxxxxxxx)xxxxxxxx

201-289-8

80-54-6

Xxxx. 1X

X360Xx

XXX08

Xxx

X360Xx“

„607-738-00-8

XXXX-xxxxxxxxx (ISO);

S-ethyl (4-chlor-2-methylfenoxy)ethanethioát; X-xxxxx 4-chlor-o-tolyloxythioacetát

246-831-4

25319-90-8

Acute Xxx. 4

XXXX RE. 2

Aquatic Xxxxx 1 Xxxxxxx Xxxxxxx 1

H302

H373 (xxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X373 (xxxxx)

X410

xxxxxx: XXX = 450 mg/kg TH

M = 10

X = 10“

„607-740-00-9

xxxxxxxxxx-xxxxxx

248-523-5

27554-26-3

Xxxx. 1X

X360XX

XXX08

Xxx

X360XX“

„607-741-00-4

4-{[(6-xxxxxxxxxxxx-3-xx)xxxxxx](2,2-xxxxxxxxxxxx)xxxxx}xxxxx-2(5X)-xx; xxxxxxxxxxxxxx

–

951659-40-8

Xxxxx Xxx. 4

XXXX RE 2

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X302

X373 (xxxxxxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X373 (xxxxxxxxx)

X410

xxxxxx: XXX = 500 xx/xx XX

X = 10

M = 10“

„607-742-00-X

xxxxxxxxxxxxx-xxxxxx (XXX);

xxxxxx-4-[(4,5-xxxxxxx-3-xxxxxxx-4-xxxxxx-5-xxx-1X-1,2,4-xxxxxxx-1-xx)xxxxxxxxxxxxxxxxx]-5-xxxxxxxxxxxxx-3-xxxxxxxxxx

–

317815-83-1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X400

X410

XXX09

Xxx

X410

X = 1000

M = 1000“

„607-743-00-5

X-(+)-xxxxxx xxxxxxxx;

(2 S)-2-hydroxypropanová xxxxxxxx

201-196-2

79-33-4

Xxxx Xxxx. 1X

Xxx Xxx. 1

H314

H318

GHS05

Dgr

H314

EUH071“

„607-744-00-0

2-methoxyethylakrylát

221-499-3

3121-61-7

Flam. Xxx. 3

Xxxx. 2

Repr. 1X

Xxxxx Xxx. 3

Xxxxx Xxx. 4

Xxxx Xxxx. 1X

Xxx Xxx. 1

Xxxx Xxxx. 1

X226

X341

X360XX

X331

X302

X314

X318

X317

XXX02

XXX05

XXX06

XXX08

Xxx

X226

X341

X360XX

X331

X302

X314

X317

XXX071

xxxxxxxxx: XXX = 2,7 mg/l (páry)

orální: XXX = 404 xx/xx XX“

„607-745-00-6

xxxxxxxxxx xxxxxxxx …%

206-058-5

298-12-4

Xxx Xxx. 1

Xxxx Xxxx. 1X

X318

X317

XXX05

XXX07

Xxx

X318

X317

X“

„607-746-00-1

xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxx;

[xxxxxxxxxxx xxxxxxxx x natrium-N-(hydroxymethyl)glycinátu]

274-357-8

70161-44-3

Carc. 1B

Muta. 2

Xxxxx Tox. 4

Xxxxx Xxx. 4

XXXX SE 3

Xxxx Xxxxx. 2

Xxx Xxxxx. 2

Skin Xxxx. 1

X350

X341

X332

X302

X335

X315

X319

X317

XXX08

XXX07

Xxx

X350

X341

X332

X302

X335

X315

X319

X317

xxxxxxxxx: XXX = 3 mg/l (xxxxx xxxx xxxx)

xxxxxx: ATE = 1 100 mg/kg XX

8

9“

„611-181-00-6

(xxxxx-XXX-xxxxx)xxxxxxxxxx xxxxxxxx;

xxxxxxxxxxxxxxxxxxxxxxx-1-xxxx, xxxxxxxx xxx;

[X-XXX]

–

66603-10-9

Xxxx. Sol. 1

Xxxxx Xxx. 3

XXXX XX 2

Xxxx Xxxxx. 2

Xxx Xxx. 1

Xxxxxxx Xxxxxxx 2

X228

X301

X373 (játra)

H315

H318

H411

GHS02

GHS06

GHS08

GHS05

GHS09

Dgr

H228

H301

H373 (játra)

H315

H318

H411

orální: XXX = 136 xx/xx XX“

„612-294-00-3

xxxxxxxxxxxxxxxxxxxxx;

X-xxxxx-X,X-xxxxxxxxxxxxxxxxx-1-xxxxxxx-xxxxx-xxxxxx;

xxxxxxxxxxx-xxxxx-xxxxxx;

[XXX]

221-106-5

3006-10-8

Xxxx Xxxx. 1

Xxx Xxx. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Chronic 1

X314

X318

X400

X410

XXX05

XXX09

Xxx

X314

X410

XXX071

X = 100

X = 1&xxxx;000 “

„613-331-00-6

(2XX)-2-[4-(4-xxxxxxxxxxx)-2-(xxxxxxxxxxxxxx)xxxxx]-1-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-2-xx;

xxxxxxxxxxxxxxxxxx

–

1417782-03-6

Xxxx Xxxx. 1

Aquatic Acute 1

Xxxxxxx Xxxxxxx 1

X317

X400

X410

XXX07

XXX09

Xxx

X317

X410

X = 1

X = 1“

„613-332-00-1

xxxxxxxxxxxxxxx (XXX);

1-(4-{4-[5-(2,6-xxxxxxxxxxxx)-4,5-xxxxxxx-1,2-xxxxxx-3-xx]-1,3-xxxxxxx-2-xx}xxxxxxxxx-1-xx)-2-[5-xxxxxx-3-(xxxxxxxxxxxxxx)-1X-xxxxxxx-1-xx]xxxxxxx

–

1003318-67-9

Xxxxxxx Xxxxxxx 1

X410

XXX09

Xxx

X410

X = 1“

„613-333-00-7

xxxxxxxxx-xxxxx; (X-4)-xxx[1-(xxxxxxx-.xxxxx.X)xxxxxxx-2(1X)-xxxxxxxx-.xxxxx.X]xxxxx

236-671-3

13463-41-7

Xxxx. 1X

Xxxxx Tox. 2

Xxxxx Xxx. 3

XXXX XX 1

Xxx Dam. 1

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X360X

X330

X301

X372

X318

X400

X410

XXX08

XXX06

XXX05

XXX09

Xxx

X360X

X330

X301

X372

X318

X410

xxxxxxxxx: XXX = 0,14 xx/x (xxxxx xxxx xxxx)

xxxxxx: XXX = 221 xx/xx XX

X = 1&xxxx;000

X = 10“

„613-334-00-2

xxxxxxxxxxxxxx (XXX);

3-xxxxx-4-(xxxxxxxxxxx)-1-[3-(xxxxxxxxxxxxxx)xxxxx]xxxxxxxxxx-2-xx

262-661-3

61213-25-0

Xxxx. 1X

Xxxxx Xxx. 4

Xxxx Xxxx. 1

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X360XX

X302

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X360XX

X302

X317

X410

xxxxxx: XXX = 500 xx/xx XX

X = 100

X = 100“

„613-335-00-8

4,5-xxxxxxx-2-xxxxx-2X-xxxxxxxxxx-3-xx; [DCOIT]

264-843-8

64359-81-5

Acute Tox. 2

Xxxxx Xxx. 4

Xxxx Xxxx. 1

Xxx Dam. 1

Xxxx Xxxx. 1 X

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

H330

H302

H314

H318

H317

H400

H410

GHS06

GHS05

GHS09

Dgr

H330

H302

H314

H317

H410

EUH071

inhalační: ATE = 0,16 mg/l (xxxxx nebo mlha)

orální: XXX = 567 xx/xx XX

Xxxx Xxxxx. 2; X315: 0,025 % ≤ X &xx; 5 %

Xxx Xxxxx. 2; X319: 0,025 % ≤ X &xx; 3 %

Xxxx Xxxx. 1 X; H317: X ≥ 0,0015 %

X = 100

M = 100“

„613-336-00-3

2-xxxxxx-1,2-xxxxxxxxxxxx-3(2X)-xx;

[XXXX]

–

2527-66-4

Xxxxx Xxx. 4

Xxxxx Xxx. 3

Xxxx Xxxx. 1X

Xxx Dam. 1

Skin Xxxx. 1 X

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 2

X312

X301

X314

X318

X317

X400

X411

XXX06

XXX05

XXX09

Xxx

X312

X301

X314

X317

X410

XXX071

xxxxxxxx: ATE = 1&xxxx;100 xx/xx TH

orální: XXX = 175 xx/xx XX

Xxxx Xxxx. 1 X; X317: X ≥ 0,0015 %

X = 1“

„616-228-00-4

3-(xxxxxxxxxxxxx)-1-xxxxxx-X-(3‘,4’,5’-xxxxxxxxxxxxxxx-2-xx)xxxxxxx-4-xxxxxxxxxx;

xxxxxxxxxxxx

–

907204-31-3

Xxxx.

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X362

X400

X410

XXX09

Xxx

X362

X410

X = 1

X = 1“

„616-230-00-5

N-(hydroxymethyl)akrylamid; xxxxxxxxxxxxxxxxx; [XXX]

213-103-2

924-42-5

Xxxx. 1X

Xxxx. 1X

XXXX XX 1

H350

H340

H372 (xxxxxxxxx xxxxxxx systém)

GHS08

Dgr

H350

H340

H372 (periferní xxxxxxx xxxxxx)“

„616-231-00-0

5-xxxxx-1,3-xxxxxxxx-X-[2-(4-xxxxxxxxxxxx-2-xx)xxxxx]-1X-xxxxxxx-4-xxxxxxxxxx; 2’-[(XX)-1,3-xxxxxxxxxxxxx]-5-xxxxx-1,3-xxxxxxxxxxxxxxx-4-xxxxxxxxxxxx;

xxxxxxxxx

–

494793-67-8

Xxxx. 2

Xxxxxxx Acute 1

Aquatic Xxxxxxx 1

X351

X400

X410

XXX08

XXX09

Xxx

X351

X410

X = 1

X = 1“

„616-232-00-6

iprovalikarb (XXX);

xxxxxxxxx [(2X)-3-xxxxxx-1-{[1-(4-xxxxxxxxxxx)xxxxx]xxxxx}-1-xxxxxxxx-2-xx]xxxxxxxx

–

140923-17-7

Xxxx. 2

X351

XXX08

Xxx

X351“

„616-233-00-1

xxxxxxxxxx (XXX);

X-xxxxx-4,5-xxxxxxxx-2-(xxxxxxxxxxxxxx)xxxxxxx-3-xxxxxxxxxx

–

175217-20-6

XXXX RE 2

Xxxxxxx Xxxxxxx 2

H373

H411

GHS08

GHS09

Wng

H373

H411“

„650-057-00-6

Margosa, výtažek [xxxx lisovaný za xxxxxxx ze semen xxxxxxxx Xxxxxxxxxxx indica xxx xxxxxxxx, extrahovaný xxxxxxxxxxxxxx xxxxxx xxxxxxxxx]

283-644-7

84696-25-3

Xxxxxxx Xxxxxxx 3

X412

X412“

2)

xxxxxxx xxxxxxxxxxxx xxxxxxxxx číslům 007-004-00-1; 014-018-00-1; 015-134-00-5; 015-181-00-1; 050-021-00-4; 050-027-00-7; 082-013-00-1; 603-014-00-0; 603-065-00-9; 605-019-00-3; 607-177-00-9; 607-256-00-8; 607-314-00-2; 609-041-00-4; 609-064-00-X; 613-112-00-5; 613-115-00-1; 613-125-00-6; 613-202-00-4; 613-259-00-5; 616–014–00–0 x 617–006–00-X xx xxxxxxxxx xxxxxx xxxxxxxxx:

Xxxxxxxx xxxxx

Xxxxxxxx xxxxx

Xxxxx ES

Číslo CAS

Klasifikace

Označení

Specifické xxxxxxx. xxxxxx, xxxxxxxxxxxxx xxxxxxx x ATE

Poznámky

Kódy xxxx x xxxxxxxxx xxxxxxxxxxxxx

Xxxx standardních xxx x xxxxxxxxxxxxx

Xxxx xxxxxxxxxxx xxxxxxx x xxxxxxxxxx xxxx

Xxxx xxxxxxxxxxxx xxx x xxxxxxxxxxxxx

Xxxx xxxxx. xxxxxxxxxxxx xxx x xxxxxxxxxxxxx

„007-004-00-1

xxxxxxxx xxxxxxx …% [X > 70 %]

231-714-2

7697-37-2

Xx. Xxx. 2

Xxxxx Xxx. 1

Skin Xxxx. 1 X

X272

X330

X314

XXX03

XXX06

XXX05

Xxx

X272

X330

X314

XXX071

Xx. Xxx. 2; X272: X ≥ 99 %

Xx. Xxx. 3; H272: 70 % ≤ X &xx; 99 %

X“

„014-018-00-1

xxxxxxxxxxxxxxxxxxxxxxxxxxx;

[X4]

209-136-7

556-67-2

Xxxx. 2

Xxxxxxx Xxxxxxx 1

X361x ***

X410

XXX08

XXX09

Xxx

X361x ***

X410

X = 10“

„015-134-00-5

xxxxxxxxx-xxxxxx (ISO);

O-[2-(diethylamin)-6-methylpyrimidin-4-yl]-O,O-dimethyl-fosforothioát

249-528-5

29232-93-7

Acute Xxx. 4

XXXX RE 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X302

X372 (xxxxxxx xxxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X372 (nervový xxxxxx)

X410

xxxxxx: XXX = 1&xxxx;414 xx/xx TH

M = 1&xxxx;000

X = 1&xxxx;000 “

„015-181-00-1

xxxxxx

232-260-8

7803-51-2

Xxxx. Gas 1

Xxxxx. Xxx

Xxxxx Xxx. 1

Xxxx Xxxx. 1X

Xxxxxxx Acute 1

X220

X330

X314

X400

XXX02

XXX04

XXX06

XXX05

XXX09

Xxx

X220

X330

X314

X400

xxxxxxxxx:

XXX = 10 xxxX (xxxxx)

X“

„050-021-00-4

xxxxxxxxxxxxxxxxxxxxx

222-583-2

3542-36-7

Xxxx. 1B

Acute Xxx. 2

XXXX RE 1

Xxxxxxx Xxxxxxx 3

H360D

H330

H372 **

X412

XXX08

XXX06

Xxx

X360X

X330

X372 **

H412

Repr. 1X; X360 X: C ≥ 0,03 %

xxxxxxxxx: XXX = 0.098 xx/X (prach nebo xxxx)“

„050-027-00-7

2-xxxxxxxxxx 10-xxxxx-4,4-xxxxxxx-7-xxx-8-xxx-3,5-xxxxxx-4-xxxxxxxxxxxxxxxxxxx; [XXXX]

239-622-4

15571-58-1

Xxxx. 1X

XXXX RE 1

Xxxxxxx Xxxxx 1

Xxxxxxx Chronic 1

X360X

X372 (xxxxxxxx systém)

H400

H410

GHS08

GHS09

Dgr

H360D

H372 (xxxxxxxx xxxxxx)

X410“

„082-013-00-1

xxxxxxx xxxxxx; [xxxxxx xxxxxx < 1 xx]

231-100-4

7439-92-1

Xxxx. 1 X

Xxxx.

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X360XX

X362

X400

X410

XXX08

XXX09

Xxx

X360XX H362

H410

Repr. 1 X; H360D: X ≥ 0,03 %

X = 1

M = 10“

„603-014-00-0

2-xxxxxxxxxxx-1-xx;

xxxxxxxxxxxxxxxxxxxxxxxxxxxx

203-905-0

111-76-2

Xxxxx Xxx. 4*

Xxxxx Tox. 4

Xxxx Xxxxx. 2

Eye Xxxxx. 2

X332

X302

X315

X319

XXX07

Xxx

X332

X302

X315

X319

xxxxxx: XXX = 1&xxxx;200 xx/xx XX“

„603-065-00-9

x-xxx(2,3-xxxxxxxxxxxx)xxxxxx;

xxxxxxxxxxxxxxxxxxxxxxxxx

202-987-5

101-90-6

Xxxx. 1X

Xxxx. 2

Xxxxx Xxx. 3

Xxxxx Xxx. 4

Skin Xxxxx. 2

Xxx Xxxxx. 2

Xxxx Xxxx. 1

Xxxxxxx Xxxxxxx 3

X350

X341

X311

X302

X315

X319

X317

X412

XXX08

XXX06

Xxx

X350

X341

X311

X302

X315

X319

X317

X412

xxxxxxxx: XXX = 300 mg/kg XX xxxxxx: ATE = 500 xx/xx XX“

„607-177-00-9

xxxxxxxxxx-xxxxxx (ISO);

methyl-2-[N-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)-N-methylkarbamoylsulfamoyl]benzoát

401-190-1

101200-48-0

STOT XX 2

Xxxx Sens. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Chronic 1

X373

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X373

X317

X410

X = 100

M = 100“

„607-256-00-8

azoxystrobin (XXX);

xxxxxx (X)-2-{2-[6-(2-xxxxxxxxxxx)xxxxxxxxx-4-xxxxx]xxxxx}-3-xxxxxxxxxxxxxx

–

131860-33-8

Xxxxx Xxx. 3

Aquatic Xxxxx 1

Xxxxxxx Xxxxxxx 1

X331

X400

X410

XXX06

XXX09

Xxx

X331

X410

xxxxxxxxx:

XXX = 0,7 xx/x (xxxxx xxxx xxxx)

X = 10

X = 10“

„607-314-00-2

ethofumesát (XXX);

(XX)-2-xxxxxx-2,3-xxxxxxx-3,3-xxxxxxxxxxxxxxxxxx-5-xx xxxxxxxxxxxxxx

247-525-3

26225-79-6

Xxxxxxx Acute 1

Aquatic Xxxxxxx 1

X400

X410

XXX09

Xxx

X410

X = 1

X = 1“

„609-041-00-4

2,4-dinitrofenol

200-087-7

51-28-5

Acute Xxx. 3 *

Xxxxx Xxx. 3

Xxxxx Xxx. 2

XXXX XX 1

Xxxxxxx Xxxxx 1

H331

H311

H300

H372

H400

GHS06

GHS08

GHS09

Dgr

H331

H311

H300

H372

H400

dermální: ATE = 300 xx/xx XX xxxxxx: XXX = 30 xx/xx XX“

„609-064-00-X

xxxxxxxxx (XXX);

2-[4-(xxxxxxxxxxxxxx)-2-xxxxxxxxxxxx]-1,3-xxxxxxxxxxxxxx

–

104206-82-8

Xxxx. 2

XXXX XX 2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X361x

X373 (xxx, nervový xxxxxx)

X400

X410

XXX08

XXX09

Xxx

X361x

X373 (xxx, nervový systém)

H410

M = 10

M = 10“

„613-112-00-5

xxxxxxxxxx (ISO);

2-oktyl-2H-isothiazol-3-on; [OIT]

247-761-7

26530-20-1

Acute Xxx. 2

Acute Xxx. 3

Xxxxx Xxx. 3

Xxxx Xxxx. 1

Eye Xxx. 1

Xxxx Xxxx. 1 X

Xxxxxxx Xxxxx 1 Xxxxxxx Xxxxxxx 1

X330

X311

X301

X314

X318

X317

X400

X410

XXX06

XXX05

XXX09

Xxx

X330

X311

X301

X314

X317

X410

XXX071

xxxxxxxxx: XXX = 0,27 xx/x (xxxxx xxxx xxxx)

xxxxxxxx: XXX = 311 xx/xx TH xxxxxx: XXX = 125 xx/xx XX

Xxxx Xxxx. 1 A; X317: C ≥ 0,0015 %

X = 100

X = 100“

„613-115-00-1

hymexazol (XXX);

3-xxxxxxx-5-xxxxxxxxxxxxxx

233-000-6

10004-44-1

Xxxx. 2

Xxxxx Tox. 4

Xxx Xxx. 1

Skin Xxxx. 1

Xxxxxxx Xxxxxxx 2

X361x

X302

X318

X317

X411

XXX08

XXX07

XXX05

XXX09

Xxx

X361x

X302

X318

X317

X411

xxxxxx: XXX = 1&xxxx;600 mg/kg XX“

„613-125-00-6

xxxxxxxxxxx (XXX);

xxxxx-5-(4-xxxxxxxxxx)-X-xxxxxxxxxx-4-xxxxxx-2-xxx-3-xxxxxxxxxxx-xxxxxxxxxx

–

78587-05-0

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

H400

H410

GHS09

Wng

H410

M = 1

X = 1“

„613-202-00-4

xxxxxxxxxx (XXX);

(X)-4,5-xxxxxxx-6-xxxxxx-4-(3-xxxxxxxxxxxxxxxxxxxxx)-1,2,4-xxxxxxx-3(2X)-xx

–

123312-89-0

Xxxx. 2

Repr. 2

Xxxxxxx Xxxxxxx 1

X351

X361xx

X410

XXX08

XXX09

Xxx

X351

X361xx

X410

X = 1“

„613-259-00-5

xxxxxxxxxxx (XXX);

xxxxxxx xxxx: [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxx-xxxxxxxxxxxxx; [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-trans-chrysanthemát

428-790-6

72963-72-5

Carc. 2

Acute Xxx. 4

Xxxxx Tox. 4

XXXX XX 2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X351

X332

X302

X371 (xxxxxxx xxxxxx; xxxxxx, xxxxxxxxx)

X400

X410

XXX08

XXX07

XXX09

Xxx

X351

X332

X302

X371 (xxxxxxx xxxxxx; orální, xxxxxxxxx)

X410

xxxxxxxxx: XXX = 1,4 xx/x (prach xxxx xxxx)

xxxxxx: ATE = 550 xx/xx XX

X = 10

M = 10“

„616-014-00-0

xxxxx-xx-xxxx; xxxxxxxxxxxxxxxxxx, xxxxx(xxxxxx)xxxxxxxxx

202-496-6

96-29-7

Xxxx. 1X

Xxxxx Tox. 4

Acute Xxx. 3

STOT XX 3

XXXX XX 1

XXXX XX 2

Xxxx Xxxxx. 2

Xxx Xxx. 1

Xxxx Xxxx. 1

X350

X312

X301

X336

X370 (xxxxx xxxxxxx xxxxx)

X373 (krevní xxxx)

X315

X318

X317

XXX08

XXX06

XXX05

Xxx

X350

X312

X301

X336

X370 (horní dýchací xxxxx)

X373 (krevní xxxx)

X315

X318

X317

xxxxxxxx: XXX = 1 100 xx/xx TH orální: XXX = 100 xx/xx XX“

„617-006-00-X

xxx(α,α-xxxxxxxxxxxxxx)xxxxxxx

201-279-3

80-43-3

Xxx. Perox. X

Xxxx. 1B

Skin Xxxxx. 2

Xxx Xxxxx. 2

Aquatic Xxxxxxx 2

H242

H360D

H315

H319

H411

GHS02

GHS08

GHS07

GHS09

Dgr

H242

H360D

H315

H319

H411“

3)

položky xxxxxxxxxxxx xxxxxxxxx xxxxxx 601-064-00-8 x 607-693-00-4 xx xxxxxxx.